El interés en corto de Silence Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Silence Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Silence Therapeutics (NASDAQ:SLN) Bolsa, Informe de interés en corto

Silence Therapeutics

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

MODV

OLMA

Descubre las principales acciones sobrevendidas del sector sanitario con RSI bajo 30, incluyendo SLN, MODV y OLMA.

Las acciones más sobrevendidas del sector sanitario con RSI bajo 30

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics PLC

SELINA HOSPITALITY PLC HS

SELINA HOSPITALITY PLC by Selina Hospitality PLC

Selina Hospitality PLC

SILENCE THERAPEUTICS ORD by Silence Therapeutics, Plc.

Southland Holdings Inc

SOLUTION FINL INC by Solution Financial Inc.

Solution Financial Inc

Stabilis Solutions Inc

Soluna Holdings Inc

Soluna Holdings, Inc. - 9.0% Series A Cumulative Perpetual Preferred Stock

STELLA INTL HLDGS LTD ORD by Stella International Holdings Ltd.

Stella International Holdings Ltd

STELLA INTL HLDG UNSP/ADR by Stella International Holdings Ltd.

SALON MEDIA GROUP INC by Salon Media Group, Inc.

Salon Media Group Inc

Soleno Therapeutics Inc

SOLUTIONS 30 SE UNSP/ADR by Solutions 30 S.E.

Solutions 30 SE

Selina Hospitality PLC Warrants (27/10/2027)

SOLANBRIDGE GROUP INC by Solanbridge Group, Inc.

Solanbridge Group Inc

TCW Senior Loan ETF

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $153 to $175.

Price Target

Analyst Ratings

GKOS

Stifel Maintains Buy on Glaukos, Raises Price Target to $175

Following discussions with the FDA and feedback from Kazia's recent Type C meeting, the FDA's current position is that data on OS would generally not be appropriate for accelerated approval, but could be considered to support a traditional/standard approval.&nbsp;
The Agency further commented that the secondary endpoint OS data from the GBM-AGILE study are supportive and informative for designing and executing a pivotal registrational study in pursuit of a standard approval.
&nbsp;Importantly, the Company aligned with the FDA on key aspects of the design of a proposed registrational/pivotal phase 3 study, including patient population, primary endpoint, and the comparator arm to be used.

KZIA

Kazia Therapeutics Updates On Paxalisib Regulatory Pathway Following Type C Meeting With FDA; Says FDA's Current Position Is That Data On OS Would Generally Not Be Appropriate For Accelerated Approval

Stifel analyst Stephen Gengaro downgrades Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) from Buy to Hold and lowers the price target from $4.5 to $0.5.

Downgrades

GOEV

Stifel Downgrades Canoo to Hold, Lowers Price Target to $0.5

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.

COCP

Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants

FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares are trading higher premarket on Tuesday. On Monday, the company launched a strategic capital initiative in <a href="https://www.benzinga.com/pressreleases/24/12/g42733059/ftai-aviation-launches-strategic-capital-initiative-and-announces-2025-financial-guidance">partnership with institutional investors.</a>
The first partnership under the initiative will focus on acquiring 737NG and A320ceo aircraft and this market opportunity will allow for the deployment of&nbsp;over $3.0 billion of capital annually.
This initiative and partnerships will allow FTAI to maintain an asset-light model while the partnerships actively acquire on-lease narrowbody aircraft at scale.
As part of this initiative, FTAI has agreed to sell 46 on-lease narrowbody aircraft to the partnership for a net purchase price of $549 million.
All engines within the partnership will utilize FTAI&#8217;s Maintenance, Repair, and Exchange services.
Outlook: FTAI expects adjusted EBITDA from its reportable segments of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1.1 billion to $1.15 billion for FY25</a>.
This includes around $500 million from Aviation Leasing and $600 to $650 million from Aerospace Products.
The company&#8217;s key assumptions include producing an average of 100 modules per quarter at the Montreal facility, maintaining or improving net Aerospace margins from 2024, and completing 25 to 35 V2500 engine MRE transactions in 2025.
As of September 30, 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41636318/ftai-aviation-ltd-reports-third-quarter-2024-results-declares-dividend-of-0-30-per-ordinary-share" rel="noreferrer noopener">cash and equivalents of $111.9 million</a>.
Investors can gain exposure to the stock via Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF (GABF) and Invesco Dorsey Wright Financial Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFI#NASDAQ">PFI</a>).
Price Action: FTAI shares are up 5.92% at $134.00 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42737644" target="_blank" rel="noreferrer noopener">US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&amp;P 500 At 7,000 In First Half Of 2025</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Guidance

Asset Sales

Movers

FTAI

PowerShares Dynamic Financial Sector Portfolio

Why Is FTAI Aviation Stock Surging Today?

As we look ahead to 2025, the technology landscape appears poised for transformation with several highly anticipated releases from industry giants.
From novel AR experiences to next-generation gaming and computing power, here&#8217;s what might shape our digital future.
Samsung&#8217;s Vision For Everyday AR
A leak this year suggested that Samsung Electronic Co&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) would leverage its partnerships with Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) to develop AI-powered smart glasses.
The device could be potentially similar to Meta Platforms, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) collaboration with Ray-Ban.
These glasses could feature advanced micro-LED displays, eye-tracking, and gesture controls. Samsung reportedly plans an initial production run of approximately 500,000 units, with a targeted release window in the third quarter of 2025.
See Also: <a href="https://www.benzinga.com/24/12/42384578/iphone-charging-cables-arent-all-safe-how-hackers-turn-them-into-tools-of-espionage">Not All iPhone Charging Cables Are Safe: Here&#8217;s How Hackers Turned Them Into Tools Of Espionage</a>
Nintendo Switch 2: Evolution Of Hybrid Gaming
Nintendo ADR&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) anticipated Switch successor looks to build upon the foundation of its predecessor. The reported 8-inch display reportedly offers a more immersive handheld experience, while magnetic Joy-Cons may provide better durability and responsiveness.
Moreover, Nintendo&#8217;s commitment to backward compatibility could reportedly ensure a smooth transition for its extensive user base. The hybrid nature of the console continues to distinguish Nintendo in the gaming market.
Apple M5 MacBook Pro: Pushing Performance Boundaries
Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) silicon journey continues with the rumored M5 chip, potentially marking another leap forward in mobile computing. While maintaining the proven design language of current MacBooks, the M5 processor could introduce architectural improvements that further separate Apple from traditional x86-based competitors.
Expected improvements in machine learning capabilities and power efficiency might enable new workflows previously impractical on portable devices.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Amazon's Finally Upgraded Alexa
Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) reportedly plans to overhaul its Alexa smart assistant in 2025, integrating generative AI for smarter, more intuitive voice commands.
The upgraded voice assistant, revealed in September 2023, was slated for release this year. It promises ChatGPT-like intelligence and more fluid, conversational exchanges.
However, a November report stated, "Alexa AI teams were recently told that their target deadline had been moved into 2025."
Apple iPad (11th Gen): Speed Boost Incoming&nbsp;
Apple is likely to launch the 11th generation of its iconic iPad in 2025. The new device will reportedly maintain a design similar to the 2022 version while offering a significant speed boost.
It&#8217;s rumored to feature either the A16 chip from the iPhone 15 or possibly an upgrade to the A17 or A18. This new iPad promises improved performance and efficiency, building on its predecessors.
With these exciting gadgets, 2025 is shaping up to be a year of major technological breakthroughs.
Photo Courtesy: Bird stocker TH On Shutterstock.com
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41061167/ios-18-includes-apples-new-passwords-app-with-end-to-end-encryption-heres-how-you-use-it">iOS 18 Includes Apple's New Passwords App with End-to-End Encryption: Here's How You Use It</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

AAPL

AMZN

GOOG

GOOGL

NTDOY

QCOM

SSNLF

Apple, Amazon, Samsung, And Nintendo: What Tech Marvels Are These Giants Cooking In 2025

As 2024 winds down, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is holding steady near its key 20-day averages. Meanwhile, Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is poised for a potential rebound, above its 50-day average.
What Happened: The technical health of these stocks can be assessed by identifying support and resistance levels, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
<h3 class="wp-block-heading">Nvidia Corp</h3>
The technical analysis of daily moving averages indicates that the stock is clinging to the support provided by its 20-day exponential moving average.
The stock ended at $137.49 apiece on Monday. This was just above its 21-day exponential moving average of $137.36 and 20-day simple moving average of $137.37. However, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, its current stock price was lower than the 50-day simple moving average of $139.96 and higher than its 200-day simple moving average of $117.63.
This implies that the stock is taking support at 20-day levels and the relative strength index of 49.91 suggests the stock&#8217;s movement is in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1024x576.png" alt="" class="wp-image-713223" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">Meta Platforms</h3>
The technical analysis of daily moving averages indicates a bullish uptrend as the stock has moved past its 50-day moving average levels.
The stock ended at $591.24 apiece on Monday. This was above its 50-day simple moving average of $587.91 and 50-day exponential moving average of $588.93. However, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, its current stock price was lower than the 20-day simple moving average of $609.59, and above its 200-day moving average of $528.11.
This implies that the stock is in an uptrend. On the other hand, the relative strength index of 46.5 suggests the stock&#8217;s movement is in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1024x576.png" alt="" class="wp-image-713225" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Why It Matters: As we head into the new year, Jim Cramer in an X post dated Dec.16, warned of a potential market correction for Nvidia on X, citing its recent surge and lack of a "crescendo moment." He predicted a "vicious" and "fast" reversal. This comes as Nvidia faces an antitrust investigation in China over its 2020 acquisition of Mellanox Technologies.
TF Securities analyst Ming-Chi Kuo expects the investigation to remain unresolved in the near term, drawing parallels to Qualcomm Inc‘s QCOM 15-month antitrust case in China.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42720866/bond-vigilantes-send-loud-warning-message-as-treasuries-climb-to-may-highs-is-the-santa-rally-in-serious-doubt-heres-what-analysts-say">Bond Vigilantes Send &#8216;Loud Warning Message&#8217; As Treasuries Climb To May Highs: Is The Santa Rally In &#8216;Serious Doubt&#8217;? Here&#8217;s What Analysts Say</a> 
JPMorgan raised Meta Platforms&#8217; price target to $725, maintaining its &#8220;overweight&#8221; rating on Dec. 1. The firm anticipates robust internet sector growth in 2025, driven by a shift in AI focus towards applications and agents. It expects increased AI spending next year from Meta and other tech leaders as they overcome 2024&#8217;s compute constraints.
Truist Securities analyst Youssef Squali maintained a &#8216;buy&#8217; rating on Meta and bumped the target price to $700 per share based on the company&#8217;s strong revenue, gross profit margin, and sustained growth potential.
Price Action: Shares of Nvidia are up 0.62% in premarket and 185.43% on a year-to-date basis, outperforming the Nasdaq 100, which was up 28.13% over the year.
According to Benzinga, Nvidia has a consensus price target of $170.56 based on the ratings of 40 analysts. The highest price target out of all the analysts <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">tracked</a> by Benzinga is $220 issued by Rosenblatt as of Nov. 21, 2024. The lowest target price is $120 issued by New Street Research on Aug. 6, 2024.
The average price target of $154.67 between DA Davidson, Phillip Securities, and Truist Securities implies an 11.83% upside for Nvidia.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NVDA/analyst-ratings"><img loading="lazy" decoding="async" width="940" height="349" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR.png" alt="" class="wp-image-713213" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR.png 940w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR-768x285.png 768w" sizes="(max-width: 940px) 100vw, 940px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/24/12/42732351/chamath-palihapitiya-says-s-p-500-index-etfs-need-to-be-fixed-or-they-will-end-in-disaster-here-is-w">Chamath Palihapitiya Says S&amp;P 500 index ETFs Need To Be &#8216;Fixed&#8217; Or They Will End In &#8216;Disaster&#8217; — Here Is What The Billionaire Investor Said</a> 
Shares of Meta are up 0.48% in premarket and 70.74% on a year-to-date basis, outperforming the Nasdaq 100, which was up 28.13% over the year.
According to Benzinga, Meta has a consensus price target of $642.51 based on the ratings of 41 analysts. The highest price target out of all the analysts <a href="https://www.benzinga.com/quote/META/analyst-ratings">tracked</a> by Benzinga is $811 issued by Rosenblatt as of Oct. 31. The lowest target price is $360 issued by Exane BNP Paribas on May 2.
The average price target of $154.67 between JPMorgan, Truist Securities, and Piper Sandler implies a 17.55 upside for Meta.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/META/analyst-ratings"><img loading="lazy" decoding="async" width="942" height="357" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR-.png" alt="" class="wp-image-713212" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR-.png 942w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR--300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR--768x291.png 768w" sizes="(max-width: 942px) 100vw, 942px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42721523/apples%20chinese-rival-huawei-slashes-prices-for-new-year-boost-should-tim-cook-led-company-be-worried-heres-what-analysts-are-saying-about-aapl-stock">Apple&#8217;s Chinese Rival Huawei Slashes Prices For New Year Boost: Should Tim Cook-Led Company Be Worried? Here&#8217;s What Analysts Are Saying About AAPL Stock</a> </li>
</ul>
Image via Shutterstock

Market Summary

Technicals

General

NVDA

Nvidia Defends Key Support As This Magnificent 7 Peer Approaches Buy Zone: Here's What Technical Analysis Says

SpaceX CEO Elon Musk said on Tuesday that the launch provider will probably carry about 99% of Earth&#8217;s payload to orbit in 2026. 
What Happened: In spite of other companies in the field of space travel growing, SpaceX will still probably launch about 99% of Earth&#8217;s payload to orbit in 2026, Musk said in a post on X. 
&#8220;Assuming rocket launches by competitors grow at their current rate, SpaceX will probably do 99.9% of payload to orbit in 10 years, but I hope I'm wrong,&#8221; the billionaire CEO said while adding that it would be &#8220;better&#8221; if rival organizations too rose up to meet his aim of taking humans to the surface of Earth&#8217;s neighboring planet Mars. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Let's not get carried away! SpaceX will probably do ~99% of Earth payload to orbit in 2026, despite the rest of industry growing. Assuming rocket launches by competitors grow at their current rate, SpaceX will probably do 99.9% of payload to orbit in 10 years, but I hope I'm…
&mdash; Kekius Maximus (@elonmusk) <a href="https://twitter.com/elonmusk/status/1873938728957428021?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to a report from Bryce Tech, SpaceX launched about 362,087 kg of spacecraft upmass in the third quarter followed by China Aerospace Science and Technology Corporation (CASC) with about 30,350 kg. While Spacex launched 518 spacecraft in the three months, CASC launched just 56. 
Why It Matters: In September, Musk said that SpaceX will launch <a href="https://www.benzinga.com/news/24/09/41022762/elon-musk-adjusts-forecast-on-spacexs-share-of-all-mass-to-orbit-if-the-rest-of-the-year-goes-well">close to 90% of all mass to orbit in 2024</a>, trumping the competition by a huge margin.
"If the rest of the year goes well, SpaceX will launch close to 90% of all mass to orbit. China will be ~6% and rest of world ~4%," Musk wrote on social media platform X.
SpaceX has completed<a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024"> 134 launches thus far</a> this year, not including four Starship test flights, marking a significant milestone. For the entirety of 2023, SpaceX only completed 96 launches, not including two test flights of the company&#8217;s Starship launch vehicle.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Kicks Off Post-Christmas Operations With Double Launch, Eyes 134 Missions In 2024</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

Elon Musk Sees SpaceX Carrying About 99% Of Earth's Payload To Orbit In 2026

GTLS

Chart Industries Received The Order From Bechtel For The Supply Of Our Integrated Pre-cooled Single Mixed Refrigerant  Liquefaction Technology And Cold Boxes For Phase 1 Of Woodside Energy Group's Louisiana LNG Development Opportunity

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from Buy to Buy.

Reiteration

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy

Cheniere Energy Achieves Their First Liquefied Natural Gas (LNG) Production From The First Train Of The Cheniere's Corpus Christi Stage 3 Liquefaction Project On December 30

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Kimbell Royalty Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>)</h3>
<ul>
<li>Dividend Yield: 10.21%</li>
<li>Truist Securities analyst Neal Dingmann maintained a Buy rating and cut the price target from $23 to $21 on Sept. 30. This analyst has an accuracy rate of 66%.</li>
<li>Raymond James analyst John Freeman maintained a Strong Buy rating and cut the price target from $22 to $20 on Jan. 24. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: Kimbell Royalty Partners will release its fourth quarter financial results on Thursday, Feb. 27, 2025, before the opening bell.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">latest KRP news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239.png" alt="" class="wp-image-713038" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239-768x709.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">HF Sinclair Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>)</h3>
<ul>
<li>Dividend Yield: 5.84%</li>
<li>Wells Fargo analyst Roger Read downgraded the stock from Overweight to Equal-Weight and cut the price target from $53 to $45 on Dec. 9. This analyst has an accuracy rate of 63%.</li>
<li>Barclays analyst Theresa Chen maintained an Equal-Weight rating and cut the price target from $44 to $42 on Nov. 11. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Oct. 31, HF Sinclair reported a third-quarter revenue decline of 19% year over year to $7.207 billion, beating the consensus of $6.833 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">latest DINO new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="722" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240.png" alt="" class="wp-image-713041" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240-300x235.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240-768x602.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</h3>
<ul>
<li>Dividend Yield: 4.46%</li>
<li>Wells Fargo analyst Roger Read downgraded the stock from Overweight to Equal-Weight and slashed the price target from $42 to $25 on Dec. 17. This analyst has an accuracy rate of 63%.</li>
<li>Citigroup analyst Scott Gruber maintained a Neutral rating and lowered the price target from $29 to $24 on Nov. 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Dec. 23, APA announced the pricing terms of cash tender offers for certain series of outstanding Apache Corporation notes.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in APA<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"> stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241.png" alt="" class="wp-image-713044" style="width:701px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241-768x703.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Dividends

DINO

Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 4% Dividend Yields

HC Wainwright &amp; Co. analyst Scott Buck maintains Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) with a Buy and raises the price target from $27 to $52.

ARQQ

HC Wainwright & Co. Maintains Buy on Arqit Quantum, Raises Price Target to $52

Tesla Inc. CEO Elon Musk changed his name on his social media platform, X, to "Kekius Maximus" (CRYPTO: KEKIUS). He also changed his profile picture to that of &#8220;Pepe the Frog&#8221; as the year 2024 draws to a close.
What Happened: Musk changing his name on X to Kekius Maximus sent the memecoin of the same name soaring more than 600% over the past 24 hours, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a>
Musk changing his profile picture to Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) also sent the coin soaring – it was up by more than 7% at the time of writing.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42735623/trump-backed-platforms-pick-years-chart-topper-6-new-cryptos-added-to-grayscales-top-20-list-with-growth-potential-in-q1-2025">Trump-Backed Platform&#8217;s Pick, Year&#8217;s Chart Topper: 6 New Cryptos Added To Grayscale&#8217;s &#8216;Top 20&#8217; List With Growth Potential In Q1 2025</a>
This is not the first time Musk has changed his profile picture or name to that of a memecoin.
Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), a well-known meme coin, has often been a favorite of Musk. On several occasions, Musk has embraced memes by changing his profile name or picture. He once updated the display picture of Twitter&#8217;s (now X) official account to feature a Shiba Inu dog, the iconic symbol of Dogecoin.
Benzinga Note: Investing in meme coins and cryptocurrencies is highly speculative and involves significant risk. Meme coins often lack intrinsic value and are driven by market sentiment, social media trends, and speculative trading. Prices can be extremely volatile, and you may lose your entire investment. Always conduct thorough research, assess your risk tolerance, and consult with a financial advisor before investing in cryptocurrencies or meme coins.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42738817/new-year-new-strategy-buy-crypto-like-you-buy-fine-wine-in-2025-experts-share-resolutions">New Year, New Strategy: Buy Crypto Like You Buy Fine Wine In 2025 — Experts Share Resolutions</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

Elon Musk Changes His Name To 'Kekius Maximus' On X, Sending This Memecoin Skyrocketing Over 600%

VRME: 253% &#x7C; <a href="https://www.benzinga.com//node/42733494">VerifyMe, Inc.: Stedham Adam H (Director, CEO and President) Buys 22,000 @ Avg Price: $0.71 (Form4)</a>
&nbsp;
NXU: 82% &#x7C; <a href="https://www.benzinga.com//node/42733027">Nxu Inc. files to sell 114.5M shares of Class A common stock for holders</a>
&nbsp;
SGMO: -64% &#x7C; <a href="https://www.benzinga.com//node/42733316">Sangamo Therapeutics Reveals Pfizer's Decision To Terminate Global Collaboration And License Agreement Between The Parties; Sangamo To Regain Full Rights to Hemophilia A Gene Therapy Program</a>
&nbsp;
&nbsp;

SGMO

VRME

Market-Moving News for December 31st

Despite a 30% decline over the last 30 days, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) continues to see rising burn rates, prompting traders to focus on its <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42715583/shiba-inu-burn-rate-soars-dogecoin-whales-on-a-buying-spree-and-more-this-week-in-crypto#:~:text=Shiba%20Inu%20Burn%20Rate%20Skyrockets,potential%20price%20rebound%20or%20reversal.">critical support levels</a>.    
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002116&nbsp;</td>
<td>$12.5 billion</td>
<td>-2.1%</td>
<td>-5.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.319</td>
<td>$47 billion</td>
<td>-0.5%</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001958</td>
<td>$8.2 billion</td>
<td>+5.6%</td>
<td>+7.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez highlighted SHIB's significant support zone between $0.0000215 and $0.0000193. 
A trader responding to the post suggested that if these levels hold, SHIB could see a potential bounce.
However, the ongoing bearish momentum increases the risk of breaking below this range. 
The trader recommended patience and strategic entries for those considering positions.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/ShibaInu?src=hash&amp;ref_src=twsrc%5Etfw">#ShibaInu</a> <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> most significant support zone is between $0.0000215 and $0.0000193! <a href="https://t.co/wgaEbvI96K">pic.twitter.com/wgaEbvI96K</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1874006326591853020?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Benzinga's technical analysis shows SHIB's RSI at 20, signaling oversold conditions and indicating a potential buy signal.
Statistics: According to Shibburn, 1.72 million SHIB were burned in the last 24 hours, with approximately 1 million SHIB burned in a single transaction six hours ago, pushing the burn rate up by 243.3%.
IntoTheBlock data shows a 1.6% decline in SHIB whale transactions, while daily active addresses remained steady at 15.5 billion. Daily transactions on Shibarium rose from 4.6 million to 4.7 million, reflecting consistent activity on the network.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42692745/shiba-inu-burn-rate-spikes-2227-whats-going-on">Shiba Inu Burn Rate Spikes 2,227%: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock

$SHIB

'Dogecoin Killer' Shiba Inu Burn Rate Surges 243%: What Is Going On?

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</h3>
<ul>
<li>On Dec. 12, Deutsche Bank analyst Steve Powers upgraded PepsiCo from Hold to Buy and raised the price target from $179 to $184. The company's stock fell around 7% over the past month and has a<a href="https://www.benzinga.com/quote/PEP"> 52-week low of $149.71</a>.</li>
<li>RSI Value: 26.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PEP Price Action: Shares of PepsiCo fell 0.8% to close at $151.72 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">latest PEP news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040714/image-236.png" alt="" class="wp-image-712997" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040714/image-236.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040714/image-236-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040714/image-236-768x707.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Mondelez International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>)&nbsp;</h3>
<ul>
<li>On Dec. 11, Mondelez International Board of Directors approved a new share repurchase program of up to $9 billion in Class A common stock, effective January 1, 2025, and lasting until December 31, 2027. This new authorization will replace the current $6 billion program, of which approximately $2.8 billion remains and would otherwise expire at the end of 2025. The company's stock fell around 9% over the past month and <a href="https://www.benzinga.com/quote/MDLZ">has a 52-week low</a> of $58.90.</li>
<li>RSI Value: 21.7</li>
<li>MDLZ Price Action: Shares of Mondelez fell 1.1% to close at $59.56 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">trend in MDLZ stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040809/image-237.png" alt="" class="wp-image-713001" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040809/image-237.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040809/image-237-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040809/image-237-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Archer-Daniels-Midland Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>)</h3>
<ul>
<li>On Dec. 11, ADM extended its share repurchase program through 2029, authorizing an additional 100 million shares for a total of 300 million. The company's stock fell around 8% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ADM">low of $48.92</a>.</li>
<li>RSI Value: 28.6</li>
<li>ADM Price Action: Shares of Archer-Daniels-Midland slipped 1% to close at $50.07 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">breakout in ADM shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040907/image-238.png" alt="" class="wp-image-713004" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040907/image-238.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040907/image-238-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31040907/image-238-768x716.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

MDLZ

Top 3 Risk Off Stocks Which Could Rescue Your Portfolio For Q4

The change is the result of January 9, 2025, being declared a National Day of Mourning to honor the late President Carter.

SMPL

Simply Good Foods Reschedules Date To Report Q1 Financial Results To January 8, 2025

Elon Musk&#8216;s EV company Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is<a href="https://www.benzinga.com/tech/24/12/42640472/tesla-exec-bemoans-cost-of-sending-letter-to-owners-affected-by-ev-giants-recent-recall-of-nearly-700000-vehicles"> recalling</a> 77,650 Model 3 and Y vehicles in China citing concerns about the tire pressure monitoring system.
What Happened: The recalled Model 3 and Y vehicles were manufactured between Sept. 28, 2021, and Nov. 22 at the company&#8217;s gigafactory in Shanghai. Tesla will fix the issue via an over-the-air software update, according to a recall notice published on China's State Administration for Market Regulation website on Tuesday.
The company is also recalling 63 imported Model S and X vehicles in China, citing concerns about potential damage to the driver&#8217;s front airbag fabric. The company said in the notice that it will replace the airbags in affected vehicles to resolve the issue. 
Why It Matters: The recall in China follows the recall of <a href="https://www.benzinga.com/markets/equities/24/12/42613937/tesla-stock-falls-over-5-during-pre-market-after-elon-musk-led-ev-giant-recalls-nearly-700000-vehicles">694,304 Cybertruck, Model 3, and Model Y vehicles</a> in the U.S. earlier this month owing to similar concerns about the tire pressure monitoring system. 
Most issues identified by Tesla in its vehicles are fixed via over-the-air updates, removing the need for vehicle owners to personally visit the service center for a fix. Tesla has issued only a few recalls this year in the U.S. or China where the fix needed a physical visit to the service center. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Kicks Off Post-Christmas Operations With Double Launch, Eyes 134 Missions In 2024</a></li>
</ul>
Photo courtesy: Shutterstock

Global

TSLA

Tesla Recalls Nearly 78,000 Model 3, Model Y Vehicles In China

11:24 EST SILENCE THERAPEUTICS (SLN) PLC SPONSORED ADR trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes

11:13 EST SILENCE THERAPEUTICS (SLN) PLC SPONSORED ADR trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

SILENCE THERAPEUTICS PLC SPONSORED ADR trading halted, volatility trading pause

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a p...

Silence Therapeutics' Promising Phase 2 Results and Growth Potential Drive Buy Rating

BMO Capital notes that Silence Therapeutics (SLN) is trading significantly lower following AHA updates due to concerns that favorable data from ora...

Silence Therapeutics weakness after AHA updates 'overdone,' says BMO Capital

Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris...

Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating

Silence Therapeutics (SLN) has released an update. Silence Therapeutics has unveiled promising Phase 1 data for their siRNA therapy, divesiran, sho...

Silence Therapeutics Advances Promising siRNA Therapy for PV

Silence Therapeutics (SLN) announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TM...

Silence Therapeutics announces additional results from SANRECO study

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Silence Therapeutics (SLN – Research Report), retaining the price target of $49.00...

Promising Prospects for Silence Therapeutics: Buy Rating Justified by Positive Phase 1 Data and Safety Profile

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stoke Therapeutics (STOK – Research Report) and Sile...

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crispr Therapeutics AG (CRSP – Research Report), Sil...

Comments

Silence Therapeutics

Interés en corto

Silence Therapeutics (NASDAQ:SLN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL